|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-9-15
|
|
pubmed:abstractText |
Prostatic cancer is resistant to chemotherapy. Expression of aldo-keto reductase 1C (AKR1C) has been associated with drug resistance and disease progression in several cancers. The aim was to investigate the relationship between AKR1C expression and disease progression in prostatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1365-2559
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 Blackwell Publishing Limited.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
384-94
|
|
pubmed:meshHeading |
pubmed-meshheading:20840669-Aged,
pubmed-meshheading:20840669-Aged, 80 and over,
pubmed-meshheading:20840669-Disease Progression,
pubmed-meshheading:20840669-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20840669-Humans,
pubmed-meshheading:20840669-Hydroxysteroid Dehydrogenases,
pubmed-meshheading:20840669-Male,
pubmed-meshheading:20840669-Middle Aged,
pubmed-meshheading:20840669-Prostatic Neoplasms,
pubmed-meshheading:20840669-Receptors, Androgen,
pubmed-meshheading:20840669-Spectrometry, Mass, Matrix-Assisted Laser...,
pubmed-meshheading:20840669-Tumor Cells, Cultured
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer.
|
|
pubmed:affiliation |
Institute of Medicine, Department of Family Medicine, Chung-Shan Medical University, Taichung, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
